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Original Article
The EUROLIGHT cluster headache
project: Description of methods and the
study population – An Internet-based
cross-sectional study of people with
cluster headache
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Abstract
Objective: To present the methodology and to describe the sample of a large, Internet-based survey on the burden of
cluster headache (CH).
Methods: Participants filled out a questionnaire online. Inclusion criteria were a reported diagnosis of CH and a residency
in a European country; exclusion criteria were refusal to give informed consent and to complete the questionnaire.
Results: A total of 1514 participants completed the questionnaire. Of these, 66.2% were male and 31.2% reported
suffering from chronic CH. The diagnosis was validated based upon the responses in 92.9% of the participants. Other
diagnoses seemed more likely in 0.8%. Among the participants with self-reported chronic CH, the International Classi-
fication of Headache Disorders-3 beta criteria for chronicity were fulfilled by 90.8%.
Conclusions: In this article, we discuss the applied methodology as well as the properties of the sample. The overall
accuracy of the self-reported diagnoses was very good as judged by our questionnaire; women and chronic CH were slightly
over-represented. We will present the results of more thorough analyses in future articles and believe that these data will
provide deeper insights into the burden of CH and will help to give a voice to those who endure this painful disease.
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Introduction
Cluster headache (CH) is a primary headache disorder
characterized by excruciatingly painful headaches and
associated autonomic symptoms.1 The attacks last between
15 and 180 min and usually occur in bouts separated by
remission periods. By definition, chronic CHs are diag-
nosed if remission lasts less than 1 month for more than
1 year according to the International Classification of
Headache Disorders (ICHD)-3 beta classification and less
than 3 months according to the ICHD-3 classification.1,2
The disease affects around 1/ 500 in the general popula-
tion3,4 and prevalence is higher among men (between 3.5:1
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and 4.3:1).5–7 Mean onset is about 30 years 8,9 – the time
when the basis is laid for a successful career and families
are found. Accordingly, previous research found that CH is
associated with a substantial burden that extends beyond
the impact of the symptoms: Two studies showed that
patients suffering from CH were less frequently employed
and required sick leave more often than controls with
migraine or tension-type headache or no headache com-
plaints at all.10,11 Also, these patients suffered more fre-
quently from depression than matched controls and often
had suicidal ideation.12,13 Other studies found that health-
related quality of life during the active phase is signifi-
cantly lower than in the general population.14,15 In addition,
for the individual patient, the disease is associated with
substantial healthcare costs.16
These study results suggest that CH attacks impose more
than pain – while the pain eventually subsides, the inter-
ictal burden persists.
Growing interest in the burden of a disease led to the
Global Burden of Disease Study 1990, in which the impact
of diseases was measured in disability-adjusted life years.17
In order to quantify the burden of headache disorders,
appropriate methods were needed. A structured question-
naire was developed and validated as part of the EURO-
LIGHT project which allowed to distinguish migraine,
tension-type headache chronic headaches, and to assess
different aspects of the burden of these major headache
disorders.18 This questionnaire was, however, not designed
to diagnose CH or to address the particularities of that
disease. In the EUROLIGHT cluster headache project,
which we present in this article, adjustments to the ques-
tionnaire were made to allow verification of the diagnostic
criteria in order to validate the diagnosis and to assess the
burden of CH via an Internet-based survey.
It is the aim of this article to present the applied meth-
odology as well as the properties of the sample. We will
discuss the results of more thorough analyses in future
articles, believing that these data will provide deeper
insights into the burden of CH and will help to give a voice
to those enduring this painful disease.
Methods
Study design and sampling method
A cross-sectional design was chosen and – due to the pre-
valence of CH and in order to limit the resources needed –
the study was designed as Internet-based. Inclusion criteria
were a self-reported diagnosis of CH and a residency in a
European country. Exclusion criteria were refusal to give
their informed consent or to complete the online question-
naire. The diagnosis was not verified prior to participation
but the questionnaire algorithm based upon the Interna-
tional Headache Society (IHS) classification2 allowed to
verify the diagnostic criteria and thereby check the validity
of the diagnosis and to control the quality of the data.
In order to include as many participants as possible,
patient associations as well as national headache societies
in Austria, Belgium, Czech Republic, Denmark, Finland,
France, Germany, Ireland, Italy, Luxembourg, the Nether-
lands, Norway, Portugal, Spain, Sweden, Switzerland and
the United Kingdom were made aware by Migraine Action
Switzerland about the study and were asked to forward
study information and the website link to eligible patients.
Potential participants not seeing a doctor or not aware of
their diagnosis, on the other hand, could not be contacted.
The website offered the questionnaire in various lan-
guages (Czech,Danish,Dutch,English, Finnish, French,Ger-
man, Italian, Norwegian, Polish, Spanish and Swedish).19
Having given their consent, participants were asked to
fill out the questionnaire anonymously; they were not fol-
lowed up or contacted a second time. The survey was pub-
lished on the Internet from May through August 2012.
Participants had to agree to fill out the questionnaire only
once. No incentives were offered for participation.
The study received financial support from the patient
association Migraine Action Switzerland as well as from
the Swiss Headache Society.
Questionnaire: Structure, development
and translation
Since symptoms, time course and treatment options of
migraine attacks and CH attacks differ, the original
EUROLIGHT questionnaire needed to be adapted for the
purpose of this study.
The questionnaire used was subdivided into two differ-
ent parts (see Online Appendix). The first part was created
with the support of headache experts from the IHS as well
as representatives of cluster patient organizations specifi-
cally for this study in order to assess the particularities of
CHs: symptom burden (items 1–12), family history (item
13), diagnosis and treatment (items 14–18) and self-injury
during headache attacks (item 19).
Questions on symptom burden were based upon the IHS
classification and assessed autonomic features accompany-
ing headache attacks, attack frequency, duration of remis-
sion periods, pain intensity, age at symptom onset, disease
duration as well as occurrence of headache attacks during
sleep. In the category ‘family history’, we inquired about
relatives suffering from CH. The ‘diagnosis and treatment’
section had the purpose to assess how and when the diag-
nosis was made and what treatment was used. In the final
section, we asked about self-injury during attacks.
In order to ensure correctness and consistency in all the
used languages, translations were carried out according to
the Lifting The Burden ‘Translation protocol for hybrid
documents’.20
The second part consisted of the EUROLIGHT ques-
tionnaire,21 from which only certain screening and diagnos-
tic questions (items 10 and 11, 17–25 as well as 31) had
been removed.
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The EUROLIGHT questionnaire is a 103-item self-
reporting questionnaire to assess the burden of primary
headache disorders and has undergone a solid validation
process.21 It consists of the following sections: social
situation questions (items 4–9), screen questions (items
10–12), daily headache questions (items 13–16), ‘most
bothersome headache’ questions (item 17), diagnostic
questions (items 18–31), questions about headache the day
before (items 32–43), healthcare questions (items 44–49),
questions on impact (items 50–56), lost time because
of headaches (items 57–61), inter-ictal burden (items
62–64), impact on social life (items 65–73), questions on
the household partner (items 74–78), body mass index
(items 79–81), the quality of life questionnaire
EUROHIS-QOL (items 82–89) and the Hospital Anxiety
and Depression Scale (items 90–103).
Questions had been adapted to the home country of the
participant whenever needed. For example, only drugs
available in the relative country were listed and household
income options were adapted to the median income of that
country.
Data analysis
As no proof of the diagnosis of CH was requested for
participation, the answers to questions about headache
duration, localization, frequency and accompanying symp-
toms were used to verify the diagnostic criteria published in
the ICHD-3 beta.2 If all criteria were met, the diagnosis
‘definite CH’ and if all but one criterion were met, the
diagnosis ‘probable CH’ were assumed. The only diagnos-
tic criterion not assessed in this study was the number of
CH attacks that the participants had already gone through.
Likewise, the diagnosis of chronic CHs was considered
valid if (i) remission time was less than 1 month and (ii) the
disease duration was more than 1 year, according to the
ICHD-3 beta criteria.
When filling out the questionnaire, participants could
decide freely whether or not they wanted to answer a ques-
tion. Therefore, missing data had to be expected. In this
article, we will refer to missing data as ‘not specified’.
Analyses were performed at the University of Basel and
University Hospital Zurich using SPSS version 25 (IBM,
Armonk, New York, USA) and Microsoft Excel 2016
(Microsoft, Redmond, Washington, USA). Categorical vari-
ables are described as proportions (%) and continuous vari-
ables in terms of means and standard deviations (SDs). We
calculated 95% confidence intervals to show associations in
bivariate analyses. Means were compared using analysis of
variance. Chi-squared and Fisher’s exact tests of signifi-
cance were used. Significance level was set at 0.05.
Results
In this article, we report on the descriptive characteristics of
the sample as well as the accuracy of the diagnosis of CH.
A total of 1827 accessed the survey online, 1795 agreed
to fill out and 1514 completed the questionnaire. By reason
of the methodology (Internet-based), the participation rate
is unknown. However, based upon epidemiological data of
the Census 201122 and the assumption of the prevalence
being about 1/500, we estimated the number of patients
suffering from CH in each country and calculated the par-
ticipation rate using these values. Participation ranged
between 0.01% and 0.62% of the theoretical maximum (see
Table 1).
More males than females participated (1000 males
(66.2%), 510 females; 4 not specified); mean age was
42.1 years + 10.9 (8 not specified). Over three-quarters
(78.0%; 31 not specified) were employed or studied and the
vast majority (74.1%; 45 not specified) were married or
living with a household partner. Participants came from
17 different countries, among which Germany, France and
the United Kingdom were named most frequently and
accounted for 59.1%. See Table 1 for further details.
Three-quarters of the participants (73.6%; 195 not speci-
fied) reported having had at least one headache attack in the
last 30 days.
Sufficient data to check the validity of the diagnosis of
CH (i.e. information on headache duration, frequency and
localization) were provided by 1439 participants (95.0%).
Fifty patients who had claimed having both uni- and bilat-
eral headaches were considered having bilateral headaches
in this analysis in order not to impair the calculations using
doubtful or incorrect data.
Among these, diagnosis seemed valid – that is, all the
criteria were met – in 1165 participants (81.0%). Of those
274, who did not meet all the criteria, a majority (225;
82.1%) deviated in exactly one criterion and will be
referred to ‘probable CH’. See Table 2 for further details.
Five participants had very frequent and short-lasting
attacks with autonomic symptoms or restlessness (0.3%)
and one (0.1%) had long-lasting (>180 min) unilateral
headaches without autonomic symptoms or restlessness.
Four participants (0.3%) had bilateral headaches without
accompanying symptoms lasting more than 30 min. For
these patients, other diagnoses than CH seemed more plau-
sible according to the ICHD.2 The numbers of patients ful-
filling the criteria for definite CH, probable CH,
paroxysmal hemicrania, migraine and tension-type head-
ache can be found in Table 2.
In this sample, 458 participants (31.2%; 48 not speci-
fied) stated suffering from chronic CH. Among these, the
diagnosis of CH was validated in 306 participants (66.8%);
only data sets with a validated diagnosis were included into
further analyses. Twenty-three patients with a validated
diagnosis of CH had not disclosed whether they suffered
from episodic or chronic CH. Their mean age was 41.9
years + 11.3; a majority (67.6%) was male. Patients with
chronic CH were significantly less frequently living with a
household partner (p ¼ 0.022) and significantly more fre-
quently being unemployed than patients with episodic CH
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(p < 0.001). See Table 3 for further details on differences in
demography between chronic and episodic CH.
Among those, who reported suffering from chronic CH,
remission duration was 2 weeks or less in a majority
(86.5%, 24 not specified). Of those 279 participants, who
had provided enough details to check the validity of their
diagnosis, some (19, 6.8%) reported usual remission time
to be 30 days or more and 1 participant (0.4%) indicated a
remission time of 90 days or more. Seven participants
(2.5%) communicated disease duration of less than 1 year.
In total, short remission periods of less than 30 days and
disease duration of at least 1 year were present in 253 cases
(90.7%). Thus, the criteria for chronicity were fulfilled by
an ample majority of those who considered themselves
suffering from chronic CH.
The portion of definite CH diagnoses was 82.9% in
participants with self-reported episodic and 66.8% in par-
ticipants with self-reported chronic CH (p < 0.001).
Discussion
The EUROLIGHT Cluster Headache Study represents a
data collection of CH patients coming from 17 European
countries. So far, there have been few large-scale studies
looking at CH patients and this manuscript presents data
from the largest EU Cluster Headache Survey ever
Table 2. Symptom frequency.
Duration (min) Localization Frequency Accompanying symptomsa Most likely diagnosis Number of participants
15–180 Unilateral Up to 8/day Present Definite CH 1165
More than 180 Unilateral Up to 8/day Present Probable CH 110
Less than 15 Unilateral Up to 8/day Present Probable CH 14
15–180 Bilateral Up to 8/day Present Probable CH 42
15–180 Unilateral More than 8/day Present Probable CH 46b
15–180 Unilateral Up to 8/day Not present Probable CH 13
5–30 Unilateral More than 8/day Present Paroxysmal hemicrania 5b
More than 180 Unilateral Not present Migrainec 1
More than 30 Bilateral Not present Tension-type headache 4
CH: cluster headache; ICHD-3: International Classification of Headache Disorders-3.
aAutonomic symptoms or restlessness.
bThree participants were listed in both categories.
cAccording to the ICHD-3 beta criteria,1 the minimal duration for migraine attacks is 4 h. In this questionnaire, the longest duration of one attack that
could be chosen was ‘more than 180 min’. Therefore, it is not possible to conclude with certainty that these patients actually fulfilled the criteria for
migraine attacks.
Table 1. Numbers of participants and demographic characteristics per country.
Country
Participants
(n (%))
Sex
(% male)
Age
(mean (SD))
Employed
or student (%)
Married or living
with partner (%)
Estimated participation
rate (%)
Austria 53 (3.5) 58.5 39.4 (10.4) 80.8 72.5 0.32
Belgium 43 (2.8) 66.7 41.2 (10.5) 75.6 77.5 0.20
Czech Republic 2 (0.1) 100.0 44.0 (9.9) 100.0 100.0 0.01
Denmark 13 (0.9) 69.2 42.1 (15.7) 69.2 69.2 0.12
Finland 67 (4.4) 53.0 43.6 (11.9) 77.3 83.3 0.62
France 304 (20.1) 66.4 39.9 (10.5) 78.6 70.9 a
Germany 345 (22.8) 69.4 42.8 (10.0) 81.0 71.3 0.22
Ireland 5 (0.3) 60.0 47.0 (11.6) 80.0 100.0 0.05
Italy 123 (8.1) 67.5 40.9 (10.6) 86.9 86.1 0.10
Luxembourg 3 (0.2) 66.7 41.0 (11.4) 100.0 100.0 0.29
The Netherlands 21 (1.4) 61.9 42.0 (12.5) 66.7 71.4 0.06
Norway 36 (2.4) 58.3 40.3 (10.3) 81.8 74.3 0.36
Poland 17 (1.1) 64.7 45.9 (12.8) 87.5 56.3 0.02
Spain 127 (8.4) 75.6 39.1 (9.0) 75.2 81.1 0.14
Sweden 55 (3.6) 60.0 44.1 (13.8) 72.7 75.0 0.29
Switzerland 54 (3.6) 74.1 40.9 (10.7) 86.8 71.2 0.34
United Kingdom 246 (16.2) 62.2 45.7 (11.5) 69.3 71.0 a
Total 1514 66.2 42.1 (10.9) 78.0 74.1 –
SD: standard deviation.
aCensus data unavailable.
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completed in Europe. Overall, the vast majority of the par-
ticipants met the diagnostic criteria for definite CH.
Despite great efforts to inform many potential participants
about the study and a large sample, the estimated partici-
pation rate is low and ranges between 0.01% and 0.62% per
country. However, most of the participants reported having
had at least one headache day within the 30 days prior to the
survey, implying that most of them were in-bout. Thus,
participation rate in the in-bout population is likely to be
higher. Unfortunately, it is not possible to reliably estimate
the number of in-bout patients per country given the fluc-
tuating durations of bouts and remission periods.23
In this sample, there were about twice as many men than
women. In population-based surveys, male/female ratios
between 3.5:1 and 4.3:1 were reported,5–7 implying that
women might be somewhat over-represented in this sam-
ple. This finding possibly reflects a sampling bias due to the
fact that more women than men participate in online sur-
veys if they are invited to do so by email.24
The questions on symptom burden enabled us to check
the validity of the CH diagnosis. Or, conversely, supposing
that the diagnosis had been made correctly, the collected
data allowed checking the accuracy of the participants’
responses. Assuming that every patient had already had
more than five attacks of his headache disorder, we can
conclude that of those who provided sufficient informa-
tion, virtually everybody fulfilled the criteria for either
CH or probable CH. Some diagnostic uncertainty became
evident, though: In six patients, the diagnosis of paroxys-
mal hemicrania seemed more likely. To our knowledge, it
has not been systematically studied, how frequently
patients initially diagnosed with CHs actually were suf-
fering from paroxysmal hemicrania. In three other
patients, migraine should be considered and two partici-
pants described symptoms, which suggest a diagnosis of
tension-type headache. In total, in 10 patients (0.7%),
other diagnoses than CH seemed more likely. We do not
know what the diagnostic procedure had consisted of in
these patients to suggest the diagnosis of CHs. Those who
reported their CHs to last less than 15 min might have
mainly considered treated attacks. Overall, the accuracy
of the diagnoses seems to be very good.
The proportion of participants in this sample suffering
from self-reported chronic CH (31.2%) was rather high. In
a Greek sample, 22.5% were reported to suffer from
chronic CH 6 and a meta-analysis of different studies found
even lower proportions of about 15%.7 This suggests a
participation bias, in the sense that those affected the most
participate more readily. Indeed, a majority of patients who
claimed suffering from chronic CHs reported remission
periods that do accord with the diagnostic criteria. Some
patients in this group, however, reported disease duration of
less than 1 year and remission periods of 30 days or even 90
days and more, which clearly points toward the diagnosis of
episodic CHs. This suggests an additional measuring bias
that might be due to remissions induced by preventive
treatments or to a misconception about the term. For
instance, some patients might believe the word ‘chronic’
refers to disease duration rather than remission time. If
confirmed, this finding would add to the critique voiced
against the use of the adjective ‘chronic’ when actually
describing short remission periods.25 In the recently pub-
lished final version of ICHD-3,1 remission durations of up
to 3 months are accepted for the diagnosis of chronic CH,
instead of 1 month in ICHD-3 beta used here. This could
have led to underestimate chronic CH in our sample. In
any case, the large number of patients suffering from
chronic CH who shared their data will allow to draw a
clearer picture of those affected the most. The fact that in
this sample, patients with chronic CH were significantly
more frequently living without a partner and being unem-
ployed more often points toward a considerable burden
worth further attention.
Conclusion
In this article, we presented the methodology as well as the
sample of the EUROLIGHT cluster headache project
which was designed to assess the burden of CH in Europe.
To that end, the collected data will be analysed thoroughly
and be presented in detail in future articles. Many individ-
uals in 17 countries agreed to participate and share their
data. In consequence, the numbers of the participants will
allow to analyse and differentiate the burden of chronic,
episodic and sex differences.
We believe that this data will provide deeper insights
into the management, specific burden and comorbidities of
CHs and will help to give a voice to those who endure this
painful disease.
Table 3. Differences in demography between patients suffering from chronic and episodic CHs; 23 participants with a validated
diagnosis of CH had not disclosed whether they suffered from episodic or chronic CH.
Episodic CH Chronic CH Significance level
Number (n (%)) 836 (73.2) 306 (26.8) –
Sex (% male) 71.0 67.6 0.28
Age (mean (SD)) 42.2 (10.4) 41.9 (11.3) 0.61
Employed or student (%) 83.7 66.3 <0.001
Married or living with partner (%) 76.0 69.2 0.02
SD: standard deviation; CH: cluster headache.
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